Lievens Chris, Pucker Andrew D, Franklin Quentin, Montaquila Stephen M, Giedd Brad, Wesley Gina, Bromley Morgan, Coker Zackarias, Meyers John, Vianya-Estopa Marta
Southern College of Optometry, Memphis, Tennessee.
Eye Research Associates, LLC, Pittsburg, Kansas.
Curr Ther Res Clin Exp. 2025 Mar 20;102:100786. doi: 10.1016/j.curtheres.2025.100786. eCollection 2025.
Perfluorohexyloctane (PFHO) acts to prevent the evaporation of the tear film. It has the potential to limit friction related issues between the eye lid margin and the ocular surface. Prior to the present work, this had not yet been evaluated.
To examine the potential of using perfluorohexyloctane for reducing the signs and symptoms of lid wiper epitheliopathy (LWE).
Data were collected at 4 visits spanning 2 months. Patients who had symptomatic dry eye and a LWE score of ≥1.0 on the Korb LWE scale were recruited. Participants were randomized to PFHO 4 times a day or no treatment. Lid wiper epitheliopathy was graded at each visit with the Korb and photographic LWE (PLWE) scales. Symptoms were assessed using the Standard Patient Evaluation of Eye Dryness questionnaire and visual analog scales (0-100).
A total of 52 participants were enrolled (mean ± SD age, 49.7 ± 15.7 years; 79% female). Right eyes in the treatment group were significantly more likely to show an improvement of ≥0.5-units in PLWE scores at 2 months than the no treatment group ( = 0.04), but no left eye differences were noted. Korb and PLWE scores were significantly better in the treatment group compared with the no treatment group starting at 2 weeks and remained so for the duration of the study (all < 0.001). Standard Patient Evaluation of Eye Dryness scores and dry eye symptoms were significantly better in the treatment than in the no treatment group at the 2-month visit (all ≤ 0.01).
Perfluorohexyloctane significantly reduced LWE and improved dry eye symptoms compared with no treatment, suggesting that PFHO may enhance ocular lubrication and reduce friction-related damage. Masked, randomized, trials are still needed to compare PFHO to other treatments in participants with LWE to support generalizability of results. ClinicalTrials.gov study NCT06671041.
全氟己基辛烷(PFHO)可防止泪膜蒸发。它有可能限制眼睑边缘与眼表之间与摩擦相关的问题。在本研究之前,尚未对此进行评估。
研究使用全氟己基辛烷减轻睑板腺上皮病变(LWE)体征和症状的可能性。
在2个月内的4次就诊时收集数据。招募有症状性干眼且Korb LWE量表评分≥1.0的患者。参与者被随机分为每天使用PFHO 4次或不进行治疗。每次就诊时使用Korb量表和摄影睑板腺上皮病变(PLWE)量表对睑板腺上皮病变进行分级。使用标准干眼患者评估问卷和视觉模拟量表(0 - 100)评估症状。
共纳入52名参与者(平均±标准差年龄,49.7±15.7岁;79%为女性)。治疗组的右眼在2个月时PLWE评分改善≥0.5个单位的可能性显著高于未治疗组( = 0.04),但左眼未观察到差异。从第2周开始,治疗组的Korb和PLWE评分显著优于未治疗组,且在研究期间一直如此(均<0.001)。在2个月的就诊时,治疗组的标准干眼患者评估问卷评分和干眼症状显著优于未治疗组(均≤0.01)。
与不治疗相比,全氟己基辛烷显著减轻了LWE并改善了干眼症状,表明PFHO可能增强眼部润滑并减少与摩擦相关的损伤。仍需要进行盲法、随机试验,以将PFHO与LWE参与者的其他治疗方法进行比较,以支持结果的普遍性。ClinicalTrials.gov研究NCT06671041。